ClinicalTrials.gg
Active, not recruitingNCT03233139Updated Feb 12, 2026

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

A Phase 1 interventional study of Cemiplimab and Ipilimumab in Advanced Malignancies, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 20 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer. The study is also being conducted to test if cemiplimab, alone or in combination, can reduce the size of your tumor by helping the immune system destroy the tumor.

Part 2 Cohorts D and E This study is being conducted to test the safety and pharmacokinetics of fianlimab and cemiplimab in patients with lung cancer. The study is also being conducted to test if fianlimab and cemiplimab, with or without chemotherapy, can reduce the size of your tumor by helping the immune system destroy the tumor.

02

Conditions studied

  • Advanced Malignancies

Keywords

  • Japanese patients
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Disease types under study:

    • Part 1: or cytologically confirmed diagnosis of with no alternative standard-of-care therapeutic option
    • Part 2: Patients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or IIIC or stage IV disease who received no prior systemic treatment for recurrent or NSCLC.
    • Patients in Part 2 NSCLC cohorts must have available archival or newly obtained formalin-fixed tumor tissue from a metastatic/recurrent site, which has not previously been irradiated.
  2. (Eastern Cooperative Oncology Group) PS (Performance status) ≤1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature [eg, light housework or office work]). Note: Patients with ECOG PS >1 are ineligible.
  3. Patients must have been born in Japan, and their biological parents and grandparents must all have been of Japanese origin
  4. Willing and able to comply with clinic visits and study-related procedures
  5. For Part 2, Cohorts D and E: Available tissue for retrospective testing using assay performed by a central laboratory, as specified in the study manual.

Key Exclusion Criteria:

  1. Ongoing or recent (within 5 years) evidence of significant disease that requires treatment with systemic treatments, which may suggest risk for Immune-mediated adverse event (imAE)s. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement or psoriasis that does not require systemic treatment.
  2. Untreated (es) that may be considered active. Patients with previously treated brain metastases may participate provided they are stable, there is no evidence of new or enlarging brain metastases, and the patient does not require any systemic for management of brain metastases within 4 weeks prior to the first dose of cemiplimab.
  3. Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of cemiplimab.
  4. Any positive test (ribonucleic acid (RNA) or Deoxyribonucleic acid (DNA) by polymerase chain reaction) for , , or indicating uncontrolled active or chronic infection.
  5. History of pneumonitis or interstitial lung disease
  6. Surgery within 1 month of first dose and radiation therapy within 2 weeks of first dose
  7. Completed palliative radiation therapy within the prior 2 weeks or has not recovered from any medically significant radiation-related Adverse Event (AE)
  8. Patients that have never smoked, defined as smoking ≤100 cigarettes in a lifetime (Part 2)
  9. Patients with tumors tested positive for epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or ROS1 fusions (Part 2)

Note: Other protocol defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Cemiplimab

    Part 1

    Drug: Cemiplimab

  • Experimental
    Cohort A

    Part 2

    Drug: Cemiplimab

  • Experimental
    Cohort B

    Part 2

    Drug: Cemiplimab · Drug: Ipilimumab · Drug: Platinum-doublet chemotherapy · Drug: Gemcitabine · Drug: Pemetrexed · Drug: Paclitaxel

  • Experimental
    Cohort C

    Part 2

    Drug: Cemiplimab · Drug: Platinum-doublet chemotherapy · Drug: Pemetrexed · Drug: Paclitaxel

  • Experimental
    Cohort D

    Part 2

    Drug: Cemiplimab · Drug: Fianlimab

  • Experimental
    Cohort E

    Part 2

    Drug: Cemiplimab · Drug: Platinum-doublet chemotherapy · Drug: Pemetrexed · Drug: Paclitaxel · Drug: Fianlimab

Interventions

  • Patients will be administered cemiplimab as per protocol. For Cohort A Only, patients with confirmed progressive disease may opt to receive up to 4 cycles of platinum doublet chemotherapy in addition to cemiplimab per investigator's judgement.

    Also known as: REGN2810, Libtayo

  • To be administered per protocol

  • DrugPlatinum-doublet chemotherapy

    To be administered per protocol

  • To be administered per protocol

    Also known as: Gemzar

  • To be administered per protocol

    Also known as: Alimta

  • To be administered per protocol

    Also known as: Taxol

  • To be administered per protocol

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) in patients treated with cemiplimab as monotherapy

    Time frame: Up to 136 weeks

  2. Incidence and severity of TEAEs in patients treated with cemiplimab in combination with other agents

    Time frame: Up to 136 weeks

  3. Incidence and severity of TEAEs in patients treated with fianlimab in combination with cemiplimab without chemotherapy

    Time frame: Up to 136 weeks

  4. Incidence and severity of TEAEs in patients treated with fianlimab in combination with cemiplimab with chemotherapy

    Time frame: Up to 136 weeks

  5. PK of cemiplimab: Cmax

    Peak serum concentration

    Time frame: Up to 136 weeks

  6. PK of cemiplimab: tmax

    Time to Cmax

    Time frame: Up to 136 weeks

  7. PK of cemiplimab: Ctrough

    Drug concentration in serum at the end of a dosing interval

    Time frame: Up to 136 weeks

  8. PK of cemiplimab: Area under the drug concentration-time curve in serum (AUC3w)

    AUC over a 3-week dosing interval

    Time frame: Up to 136 weeks

  9. PK of cemiplimab: t½ estimated over a 3-week dosing interval

    Observed terminal half-life

    Time frame: Up to 136 weeks

Secondary outcomes

  1. Immunogenicity against cemiplimab and fianlimab

    Evaluate the immunogenicity of cemiplimab and fianlimab after single-dose administration

    Time frame: Up to 136 weeks

  2. Objective Response Rate (ORR)

    As assessed by an Independent Review Committee (IRC) using RECIST 1.1 (Eisenhauer 2009) in Part 2, Cohorts A and C

    Time frame: Up to 135 weeks

  3. Duration of Response (DOR)

    As assessed by an IRC (per RECIST1.1) in Part 2, Cohorts A and C

    Time frame: Up to 136 weeks

07

Study locations

20 sites
08

References and documents

Publications

  • Kitano S, Shimizu T, Koyama T, Ebata T, Iwasa S, Kondo S, Shimomura A, Fujiwara Y, Yamamoto N, Paccaly A, Li S, Rietschel P, Sims T. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemother Pharmacol. 2021 Jan;87(1):53-64. doi: 10.1007/s00280-020-04161-6. Epub 2020 Nov 4. PubMed 33146741 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2017 (actual). Primary completion is estimated for Sep 2027, 123 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2017
First posted
Jul 28, 2017
StartActual
Jun 21, 2017
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03233139
Responsible party
Sponsor
First posted
Jul 28, 2017
Start date
Jun 21, 2017
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion